Company intelligence / Profile preview

Countstar

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Countstar is a leading provider of automated cell analysis platforms, combining digital microscopy, fluorescence imaging, and flow cytometry functions to streamline cell counting and viability analysis in GMP-compliant bioprocess, therapeutic cell manufacturing, and research applications. Over 2,000 systems installed worldwide; the platform supports multi-channel analysis (viability, apoptosis, cell cycle, cytotoxicity, transfection, phenotyping)

Modalities: DeviceInstrumentation
Industry: Drug Discovery Services

Partnerships

De Novo Software (data analysis software integration for Countstar Rigel fluorescence cell analyzer)DKSH (distribution in Malaysia and other regions)

Beyond the preview

Go deeper on Countstar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Countstar.

Explore the full profile